Hasil Pencarian - SECOND-LINE

  • Menampilkan 1 - 2 hasil dari 2
Perbaiki Hasil
  1. 1
    HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.

    HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-l... oleh Allison Martin, Cecilia L Moore, Patrick W G Mallon, Jennifer F Hoy, Sean Emery, Waldo H Belloso, Praphan Phanuphak, Samuel Ferret, David A Cooper, Mark A Boyd, Second-Line Study Team

    Diterbitkan 2013-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Correction: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection.

    Correction: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of... oleh Janaki Amin, Mark A Boyd, Nagalingeswaran Kumarasamy, Cecilia L Moore, Marcello H Losso, Chidi A Nwizu, Lerato Mohapi, Stephen J Kerr, Annette H Sohn, Hedy Teppler, Boris Renjifo, Jean-Michel Molina, Sean Emery, David A Cooper, SECOND-LINE

    Diterbitkan 2015-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: